Ionis nets Zanvastro US approval in first for Alexander disease - Pharmaceutical Technology

Ionis claims Zanvastro will become available to US patients with rare neurodegenerative condition, Alexander disease “in the coming weeks”. Ionis claims Zanvastro will become available to US patients with Alexander disease “in the coming weeks”. Zanvastro has now become the first disease-modifying therapy to secure FDA approval in Alexander disease. Credit: Khan Vector Co / Shutterstock.com. Ionis Pharmaceuticals has secured an approval from the US Food and Drug Administration (FDA) for its therapy, zilganersen, in the rare neurodegenerative disorder Alexander disease – marking the first time a disease-modifying therapy has debuted in this indication. Following the FDA’s go-ahead, the antisense…

Source: Pharmaceutical Technology